N-[1-(2-diethylamino-ethylamino)-7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl]formamide | 155990-20-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 硫色烯
• 英文名称: N-[1-(2-diethylamino-ethylamino)-7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl]formamide
• 英文别名: N-[[ 1-[[2-(Diethylamino)ethyl]amino]-7-methoxy-9-oxothioxanthen-4-yl]methyl]formamide；N-[1-[2-(diethylamino)ethylamino]-7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl]formamide；N-[[1-[[2-(diethylamino)ethyl]amino]-7-methoxy-9-oxothioxanthen-4-yl]methyl]formamide；N-[1-[2(diethylamino)ethylamino]-7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl]formamide；Formamide, N-((1-((2-(diethylamino)ethyl)amino)-7-methoxy-9-oxo-9H-thioxanthen-4-yl)methyl)-；N-[[1-[2-(diethylamino)ethylamino]-7-methoxy-9-oxothioxanthen-4-yl]methyl]formamide
• CAS: 155990-20-8
• 化学式: C₂₂H₂₇N₃O₃S
• 分子量: 413.541
• InChiKey: GWLFIMOOGVXSMZ-UHFFFAOYSA-N

物化性质

• 熔点：
  95-99 °C
• 沸点：
  670.4±55.0 °C(Predicted)
• 密度：
  1.237±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  29
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  96
• 氢给体数：
  2
• 氢受体数：
  6

制备方法与用途

SW 71425能够抑制乳腺、结肠、非小细胞肺癌以及卵巢肿瘤的细胞生长。

反应信息

• 作为反应物：
  描述：

  N-[1-(2-diethylamino-ethylamino)-7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl]formamide 在 吡啶 、 盐酸 作用下， 反应 3.0h， 生成 N-[[1-[[2-(diethylamino)ethyl]amino]-7-methoxy-9-oxothioxanthen-4-yl]methyl]methanesulfonamide
  参考文献：
  名称：

  Synthesis and Antitumor Activity of 4-Aminomethylthioxanthenone and 5-Aminomethylbenzothiopyranoindazole Derivatives

  摘要：

  Two new series of antitumor agents, 4-aminomethylthioxanthenones (6-50) and 5-aminomethylbenzothiopyranoindazoles (51-61), are described and compared. Nearly all members of both series display excellent in vivo activity versus murine pancreatic adenocarcinoma 03 (Panc03) although there is little to distinguish the two series from each other. In both series there is no discernible relationship between structure and in vivo efficacy. Selected analogues were evaluated in vitro; all were observed to have moderate to strong DNA binding via intercalation. However, varying degrees of in vitro P388 cytotoxicity and topoisomerase II inhibition were seen. In general, those molecules which exhibited strong topoisomerase II inhibition were significantly more cytotoxic than those which did not. In both series, those derivatives (48-50, 60, and 61) having a phenolic hydroxy substitution exhibited the most potent P388 cytotoxicity and topoisomerase II inhibition.

  DOI：

  10.1021/jm9708083
• 作为产物：
  描述：

  1-[[2-(diethylamino)ethyl]amino]-7-methoxy-9-oxothioxanthen-4-carboxaldehyde 以69的产率得到N-[1-(2-diethylamino-ethylamino)-7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl]formamide
  参考文献：
  名称：

  Thioxanthenone antitumor agents

  摘要：

  本文介绍了1-[[(二烷基氨基)烷基]氨基]-4-取代硫代黄酮-9-酮作为抗肿瘤剂的应用。同时还公开了含有硫代黄酮酮类化合物的组合物以及使用该类化合物治疗哺乳动物肿瘤和癌症的方法。

  公开号：

  US05346917A1

文献信息

• Spirocyclic compounds
  申请人：Berk C. Scott

  公开号：US20070117824A1

  公开（公告）日：2007-05-24

  The present invention relates to a novel class of substituted spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.

  本发明涉及一类新型的取代螺环化合物。这些化合物可以抑制组蛋白去乙酰化酶，并适用于在选择性诱导终末分化、阻止肿瘤细胞生长和/或凋亡的过程中使用，从而抑制这些细胞的增殖。因此，本发明的化合物在治疗具有肿瘤特征的患者方面是有用的，这些肿瘤具有肿瘤细胞的增殖。本发明的化合物还可能在预防和治疗TRX介导的疾病方面有用，例如自身免疫、过敏和炎症性疾病，以及预防和/或治疗中枢神经系统（CNS）疾病，如神经退行性疾病。本发明还提供了包括本发明化合物的药物组合物和这些药物组合物的安全用药方案，这些方案易于遵循，并在体内产生这些化合物的治疗有效量。
• [EN] MITOTIC KINESIN INHIBITORS<br/>[FR] INHIBITEUR DE KINESINES MITOTIQUES
  申请人：MERCK & CO INC

  公开号：WO2003105855A1

  公开（公告）日：2003-12-24

  The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

  本发明涉及对二氢吡咯烷化合物，其用于治疗细胞增殖性疾病，治疗与KSP动力蛋白活性相关的疾病，以及抑制KSP动力蛋白。该发明还涉及包含这些化合物的组合物，以及使用它们治疗哺乳动物癌症的方法。
• Polymorphs with tyrosine kinase activity
  申请人：——

  公开号：US20040023980A1

  公开（公告）日：2004-02-05

  The present invention relates to active polymorphs of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.

  本发明涉及活性多型体4-[2-(5-氰基噻唑-2-基氨基)-吡啶-4-基甲基]-哌嗪-1-羧酸甲酰胺，其抑制、调节和/或调控酪氨酸激酶信号传导，含有这些化合物的组合物，以及使用它们治疗酪氨酸激酶依赖性疾病和症状的方法，如血管生成、癌症、肿瘤生长、动脉粥样硬化、老年性黄斑变性、糖尿病视网膜病变、视网膜缺血、黄斑水肿、炎症性疾病等在哺乳动物中。
• Mitotic kinesin inhibitors
  申请人：Coleman J. Paul

  公开号：US20050176776A1

  公开（公告）日：2005-08-11

  The present invention relates to substituted thiazole derivatives that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin and MCAK activity, and for inhibiting KSP kinesin and MCAK. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

  本发明涉及用于治疗细胞增殖性疾病、治疗与KSP动力蛋白和MCAK活性相关的疾病，以及抑制KSP动力蛋白和MCAK的取代噻唑衍生物。该发明还涉及包含这些化合物的组合物，以及利用它们治疗哺乳动物癌症的方法。
• Substituted Imidazopyridines as HDM2 Inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20140179680A1

  公开（公告）日：2014-06-26

  The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

  本发明提供了如本文所述的取代咪唑吡啶或其药用可接受的盐或溶剂。代表性化合物可用作HDM2蛋白的抑制剂。还公开了包括上述化合物的药物组合物以及使用它们治疗癌症的潜在方法。